Download pdf
Drug Patent Link System in CPTPP and China’s Response
- 1 China University of Political Science and Law
- 2 Ocean University of China
* Author to whom correspondence should be addressed.
Abstract
With the reform of the international intellectual property system, the intellectual property rules in regional trade agreements are gradually leading the development of the international intellectual property system. On September 16, 2021, China formally applied to join the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP). The CPTPP intellectual property rules will have a profound impact on China's intellectual property legal system. CPTPP stipulates the drug patent link system, and China is also trying to build a drug patent link system. In order to integrate with CPTPP intellectual property rules and build a drug patent link system in line with China's national conditions, it is suggested to further clarify the patent availability standards of pharmaceutical inventions, simplify the drug marketing approval procedures and improve the patent invalidation procedures.
Keywords
CPTPP, drug patent link, patent review, drug approval
[1]. Xie Wei, Ma Zhiguo, Zhang Lei.Study on Systematic Route Selection of Pharmaceutical Patent Link in China [J].China Science and Technology Forum, 2021 (05): 108-117.
[2]. Li Qing.Related market definition of the reverse payment agreement under the drug patent link [J].Journal of Anhui University of Technology (Social Science edition), 2021,38 (02): 38-40.
[3]. Wei Cong, Tian Tian, Du Guoshun, Yin Xin.Institutional design of early resolution mechanism of drug patent disputes with Chinese characteristics —— takes the perspective of comparing foreign experience and domestic current situation [J].Chinese Journal of New Drugs, 2021,30 (15): 1345-1354.
[4]. Li Qing.On the Improvement of the Drug Patent Link System in China [J].Journal of Southwest Petroleum University (Social Sciences edition), 2021,23 (06): 41-48.
[5]. Liu Lichun, Zhu Xuezhong.Selection of elements of the drug patent link system in the United States and Canada and its implications for China [J].China Science and Technology Forum, 2014 (01): 147-154.
[6]. Zhang Haoran.Inheritance and adjustment of Chinese drug patent link system under the competitive vision [J].Intellectual Property Rights, 2019 (04): 50-70.
[7]. Ouyang Ning, Gu Donglei.Visualization and comparative analysis of Chinese and foreign drug patent links [J].Chinese Medical Library and Information Journal, 2019,28 (08): 58-64.
[8]. Yuan Lin, Wu Zhi-Ang, Shao Mingli.Evolution of the registration regulations for proprietary Chinese medicines in China[J].Chinese Journal of Natural Medicines,2017,15(01):4-11.
Cite this article
Hao,M.;Ma,R. (2022). Drug Patent Link System in CPTPP and China’s Response. Theoretical and Natural Science,1,6-9.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title:
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).